The study compound could potentially be used for the treatment of autoimmune disorders. The human body is continuously producing new cells. To stay healthy, it is important for the body to also be able to clean up cells.  The death of cells that are no longer needed has to be strictly regulated in the body. However, with autoimmune diseases, something goes wrong when clearing away cell remnants. Too many cells die. The study compound inhibits this to stop the disease from worsening.

The compound has already been extensively tested in the laboratory and in animals, in addition it has been tested in healthy individuals and patients with autoimmune disorders. The compound was well-tolerated. Side effects that were reported most frequently included headaches and drowsiness. You may experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask questions to the screening physician or nurse. Once everything is clear to you, you can decide to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

• You are a healthy male or female.
• You are at least 18 and at most 45 years old.
• Your Body Mass Index (BMI) is at least 18.0 and at most 32.0 kg/m², and as a male you weigh at least 50.0 kg and at most 100.0 kg, and as a female you weigh at least 40.0 kg and at most 90.0 kg.
• Both non-smokers and light smokers or occasional smokers (no more than 5 cigarettes per week) are allowed to participate in this clinical trial. During your stay in our research facility you are not allowed to smoke.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 60 days prior to the admission in this clinical trial (counting from the last dosing in the previous trial).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.
• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You are using hormonal contraception (for example the contraceptive pill or intra-uterine device containing hormones) in combination with a condom;
  • You are using a copper intra-uterine device;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized or your male partner has been sterilized;
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.
  • As a male you can only participate if you meet one of the following conditions:
    • You are using a condom in combination with an additional contraception method used by your female partner;
    • Your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
    • You are not sexually active according to your lifestyle;
    • You are only sexually active with a partner of the same sex.

The trial consists of 3 periods during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 4 days (3 nights). The follow-up visit will take place 5 to 7 days after your final departure from the research facility.

Note: You must be available for all dates to be able to participate in this clinical trial.